AIM
ACOR

Advantage Investment Management’s Acorda Therapeutics ACOR Stock Holding History

Advantage Investment Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4
Closed -$12K – 1058
2018
Q1 		$12K Buy
+4
New +$12K ﹤0.01% 650

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Advantage Investment Management's ACOR Position: Q2 2018 in Review

Advantage Investment Management sold out of Acorda Therapeutics (ACOR) in Q2 2018, closing a stake of 4 shares — an estimated $12K sold.

Advantage Investment Management first reported a position in ACOR in Q1 2018 and held it in 1 quarter. The position peaked at $12K in Q1 2018. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2018.

  • Advantage Investment Management reported no remaining Acorda Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Advantage Investment Management sold 4 Acorda Therapeutics shares in Q2 2018, an estimated $12K.
  • Advantage Investment Management first reported a position in Acorda Therapeutics in Q1 2018 and held it in 1 quarter.
  • Advantage Investment Management's Acorda Therapeutics position peaked at $12K in Q1 2018.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2018.

Based on Advantage Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.